|Description:||1. 4-Beta-Hydroxycholesterol has exceptionally slow elimination and high plasma concentration properties, may it is a potential role of 4-Beta-Hydroxycholesterol as a ligand for the nuclear.|
2. 4-Beta-hydroxycholesterol is a new endogenous CYP3A marker.
|Targets:||P450 (e.g. CYP17) | Liver X Receptor|
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: email@example.com
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||2.4835 mL||12.4174 mL||24.8348 mL||49.6697 mL||62.0871 mL|
|5 mM||0.4967 mL||2.4835 mL||4.967 mL||9.9339 mL||12.4174 mL|
|10 mM||0.2483 mL||1.2417 mL||2.4835 mL||4.967 mL||6.2087 mL|
|50 mM||0.0497 mL||0.2483 mL||0.4967 mL||0.9934 mL||1.2417 mL|
|100 mM||0.0248 mL||0.1242 mL||0.2483 mL||0.4967 mL||0.6209 mL|
J Biol Chem. 2002 Aug 30;277(35):31534-40.
|Metabolism of 4 beta -hydroxycholesterol in humans.[Pubmed: 12077124]|
|One of the major oxysterols in the human circulation is 4-Beta-Hydroxycholesterol formed from cholesterol by the drug-metabolizing enzyme cytochrome P450 3A4. Deuterium-labeled 4-Beta-Hydroxycholesterol was injected into two healthy volunteers, and the apparent half-life was found to be 64 and 60 h, respectively. We have determined earlier the half-lives for 7 alpha-, 27-, and 24-hydroxycholesterol to be approximately 0.5, 0.75, and 14 h, respectively. Patients treated with certain antiepileptic drugs have up to 20-fold increased plasma concentrations of 4-Beta-Hydroxycholesterol. The apparent half-life of deuterium-labeled 4-Beta-Hydroxycholesterol in such a patient was found to be 52 h, suggesting that the high plasma concentration was because of increased synthesis rather than impaired clearance. 4-Beta-Hydroxycholesterol was converted into acidic products at a much slower rate than 7 alpha-hydroxycholesterol in primary human hepatocytes, and 4-Beta-Hydroxycholesterol was 7 alpha-hydroxylated at a slower rate than cholesterol by recombinant human CYP7A1. CYP7B1 and CYP39A1 had no activity toward 4-Beta-Hydroxycholesterol. These results suggest that the high plasma concentration of 4-Beta-Hydroxycholesterol is because of its exceptionally slow elimination, probably in part because of the low rate of 7 alpha-hydroxylation of the steroid. The findings are discussed in relation to a potential role of 4-Beta-Hydroxycholesterol as a ligand for the nuclear receptor LXR.|
J Biol Chem. 2001 Oct 19;276(42):38685-9.
|Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.[Pubmed: 11514559 ]|
|The major cholesterol oxidation products in the human circulation are 27-hydroxycholesterol, 24-hydroxycholesterol, and 7alpha-hydroxycholesterol. These oxysterols are formed from cholesterol by specific cytochrome P450 enzymes, CYP27, CYP46, and CYP7A, respectively. An additional oxysterol present in concentrations comparable with 7alpha- and 24-hydroxycholesterol is 4-Beta-Hydroxycholesterol. We now report that patients treated with the antiepileptic drugs phenobarbital, carbamazepine, or phenytoin have highly elevated levels of plasma 4-Beta-Hydroxycholesterol. When patients with uncomplicated cholesterol gallstone disease were treated with ursodeoxycholic acid, plasma 4-Beta-Hydroxycholesterol increased by 45%. Ursodeoxycholic acid, as well as the antiepileptic drugs, are known to induce cytochrome P450 3A. Recombinant CYP3A4 was shown to convert cholesterol to 4beta-hydroxycholesterol, whereas no conversion was observed with CYP1A2, CYP2C9, or CYP2B6. The concentration of 4-alpha-hydroxycholesterol in plasma was lower than the concentration of 4beta-hydroxycholesterol and not affected by treatment with the antiepileptic drugs or ursodeoxycholic acid. Together, these data suggest that 4-Beta-Hydroxycholesterol in human circulation is formed by a cytochrome P450 enzyme.|
Pharmacogenet Genomics. 2008 Mar;18(3):201-8.
|4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.[Pubmed: 18300941]|
|To study the potential endogenous marker of CYP3A activity, 4-Beta-Hydroxycholesterol, and its relation to sex and the CYP3A5 geno/haplotypes and compare with CYP3A4/5 catalyzed 3-hydroxylation of quinine in the three major races. METHODS: The plasma concentration of 4-Beta-Hydroxycholesterol was measured in healthy Tanzanians (n=138), Swedes (n=161) and Koreans (n=149) by gas chromatography-mass spectrometry. The metabolic ratio of quinine/3-hydroxyquinine in plasma 16-h post dose was determined by high performance liquid chromatography, previously reported in Tanzanians and Swedes, and now also in Koreans. The participants were genotyped for relevant alleles of CYP3A5. Clear differences in the activity of both CYP3A4 and CYP3A5 were shown in the three major human races. Both 4-Beta-Hydroxycholesterol and quinine/3-hydroxyquinine metabolic ratio showed a higher CYP3A activity in women than in men. The results give strong evidence that the plasma concentration of 4-Beta-Hydroxycholesterol may be used as an endogenous marker of CYP3A activity (CYP3A4+5).|